The FDA appears to have won its staring contest with Sarepta over shipments of Elevidys, after the company blinked and agreed ...

The company agreed to voluntarily halt shipments of its experimental medicine Elevidys for Duchenne muscular dystrophy.

Sarepta will halt all shipments of Elevidys, its drug for Duchenne muscular dystrophy patients, by Tuesday evening.